reports
DSS, Inc. Announces Sale of Celios® to Impact BioMedical, Streamlining...
DSS, Inc. Announces Sale of Celios® to Impact BioMedical, Streamlining Portfolio for Strategic Growth ROCHESTER, N.Y., Feb. 26, 2025 (GLOBE NEWSWIRE) -- DSS, Inc. (NYSE American: DSS), a multinational company focused on innovation-driven business models, today announced the sale of its Celios® air purification asset to Impact BioMedical Inc. (NYSE American: IBO) in a strategic, all-equity transaction valued at approximately $1.15 million. This divestiture aligns with DSS’ ongoing strategy to optimize its portfolio and concentrate on core growth areas. Celios® is a cutting-edge air purifi...
DSS, Inc. Issues Letter to Shareholders
DSS, Inc. Issues Letter to Shareholders NEW YORK, Feb. 03, 2025 (GLOBE NEWSWIRE) -- DSS, Inc. (NYSE American: DSS) a multinational company operating businesses within diversified market sectors that strategically acquires and develops assets to increase shareholder value, today issued the following letter to shareholders: Dear Esteemed Shareholders, I am pleased to provide you with significant updates regarding the leadership of DSS, Inc. and to outline the strategic direction we are pursuing as a Company. It is with great honor that I announce my appointment as Interim Chief Executive...
DSS Inc: 1 director
A director at DSS Inc bought 1,025,746 shares at 0.975USD and the significance rating of the trade was 75/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly sho...
DSS, Inc. Celebrates Impact BioMedical Inc.'s Successful IPO and Proud...
DSS, Inc. Celebrates Impact BioMedical Inc.'s Successful IPO and Proudly Advances Shareholder Value NEW YORK, Sept. 16, 2024 (GLOBE NEWSWIRE) -- DSS, Inc. (NYSE American: DSS), a dedicated supporter and investor in Impact BioMedical Inc. (NYSE American: IBO), is delighted to announce the successful pricing of Impact BioMedical's initial public offering (IPO). Impact BioMedical, a trailblazer in advancing human healthcare and wellness solutions, has set its IPO price at $3.00 per share, with an initial offering of 1,500,000 shares. Trading under the ticker symbol “IBO,” these shares will b...
AmericaFirst Funds Trust Announces Changes to Board of Trustees
AmericaFirst Funds Trust Announces Changes to Board of Trustees NEW YORK, Sept. 10, 2024 (GLOBE NEWSWIRE) -- AmericaFirst Funds, a subsidiary of DSS, Inc. (NYSE American: DSS), today announced that effective August 9, 2024, David Friedensohn, Monica Himes and Allan Siegel have resigned from their positions as independent directors. The Trust is pleased to announce the election of three new independent directors by shareholder proxy vote: Dr. Prabir Datta, Darryl Robinson and Mark Gronet. These individuals are seasoned senior investment executives who bring a wealth of experience and ...
DSS, Inc. Names Jason Grady as Interim Chief Executive Officer
DSS, Inc. Names Jason Grady as Interim Chief Executive Officer NEW YORK, Aug. 26, 2024 (GLOBE NEWSWIRE) -- DSS, Inc. (NYSE American: DSS) has announced the appointment of Jason Grady as its Interim CEO, effective August 23, 2024. Grady, who previously served as Chief Operating Officer of DSS, Inc., brings over 25 years of extensive experience in executive leadership, business development, restructuring, and operations management across a variety of industries. He will succeed Frank D. Heuszel, who is exiting the company to transition to a leadership role within one of its former subsidiar...
Impact Biomedical, Inc. Announces U.S. Patent Allowance of Laetose™ Te...
Impact Biomedical, Inc. Announces U.S. Patent Allowance of Laetose™ Technology Entitled "Low Glycemic Sugar Composition." NEW YORK, Jan. 30, 2024 (GLOBE NEWSWIRE) -- Impact Biomedical Inc. (IBIO), in which DSS Inc.(NYSE American: DSS) has a significant investment, is thrilled to announce a milestone in its innovative Laetose™ technology platform. The U.S. Patent and Trademark Office (USPTO) has issued U.S. patent # 11,898,184, entitled "Low Glycemic Sugar Composition" developed within this platform. The Laetose™ technology demonstrates compelling potential in reducing caloric intake and ...
DSS, Inc. Chairman Chan Acquires 672,173 shares of DSS In Open Market
DSS, Inc. Chairman Chan Acquires 672,173 shares of DSS In Open Market Chairman of the Board Heng Fai Ambrose Chan Adds 672,173 Shares to Increase Investment in Company NEW YORK, Jan. 04, 2024 (GLOBE NEWSWIRE) -- DSS, Inc. (NYSE American: DSS, “Company”), a multinational company operating across four distinct market sectors, announced today a significant investment by its Chairman of the Board, Heng Fai Ambrose Chan. In a strategic move to bolster shareholder confidence and underscore his commitment to the company’s growth. Chairman Chan acquired an additional 672,173 shares of DS, Inc. ...
DSS, Inc. Announces Reverse Split as Part of NYSE American Compliance ...
DSS, Inc. Announces Reverse Split as Part of NYSE American Compliance Plan NEW YORK, Dec. 22, 2023 (GLOBE NEWSWIRE) -- DSS, Inc. (NYSE American: DSS, “Company”), a multinational company operating nine (9) diversified business lines developed through strategic acquisitions to build shareholder value through periodic spinoffs to its shareholders, today announced that it will proceed with a 1-for-20 reverse stock split (the “Reverse Split”) of its issued and outstanding shares of common stock, par value $0.02, following authorization by its Board of Directors and majority shareholders to eff...
Premier Packaging, a Wholly-Owned Subsidiary of DSS, Inc., Secures Con...
Premier Packaging, a Wholly-Owned Subsidiary of DSS, Inc., Secures Contract Extension with Major Retailer Worth Up to $15 Million over Four Years Option for Fourth Year Brings Potential Revenue to Over $15 Million NEW YORK, Nov. 28, 2023 (GLOBE NEWSWIRE) -- DSS, Inc. (NYSE American: DSS), a multinational company operating nine (9) diversified business lines developed through strategic acquisitions to build shareholder value through periodic spinoffs to its shareholders, announced today that its wholly-owned subsidiary, , signed a contract extension with an existing client for the next t...
DSS Inc. Wins Patent Dispute with Nichia Corporation
DSS Inc. Wins Patent Dispute with Nichia Corporation NEW YORK, Nov. 14, 2023 (GLOBE NEWSWIRE) -- DSS, Inc. (NYSE American: DSS) announced today that, in a unanimous decision, the Court of Appeals for the Federal Circuit (CAFC) rejected Nichia Corp.'s challenge to U.S. Patent No. 6,879,040 (the ‘040 Patent). U.S. Chief Circuit Judge Kimberly Moore, who authored the opinion, and U.S. Circuit Judges Kara Stoll and Tiffany Cunningham sat on the panel for the Federal Circuit. The CAFC appeal mounted by Nichia Corp., a Japanese electronics company, asserted that a 2021 Inter Partes Review ...
DSS, Inc. Subsidiary Files Current Report on Form 8-K Disclosing Rever...
DSS, Inc. Subsidiary Files Current Report on Form 8-K Disclosing Reverse Split of Outstanding and Issued Common Stock and Conversion of Certain Holder’s Common Stock DSS Shareholders to Benefit from Reduction in Common Stock of Impact Biomedical NEW YORK, Nov. 08, 2023 (GLOBE NEWSWIRE) -- DSS, Inc. (NYSE American: DSS) announced today that Impact BioMedical Inc. (“Impact”) filed a Current Report on Form 8-K with the Securities and Exchange Commission on November 6, 2023, disclosing that Impact effected a reverse stock split of its issued and outstanding common stock by a ratio of 1 for ...
DSS Inc. Receives Notice of Non-Compliance with NYSE American Trading ...
DSS Inc. Receives Notice of Non-Compliance with NYSE American Trading Share Price Listing Rule Company intends to cure the deficiency and return to compliance with NYSE American standard NEW YORK, Oct. 26, 2023 (GLOBE NEWSWIRE) -- DSS, Inc.(NYSE American: DSS) announced today that the Company received a letter (the “Letter”) from the staff of NYSE American LLC (the “Exchange”) stating that the Company’s securities have been selling for a low price per share for a substantial period of time and, pursuant to Section 1003(f)(v) of the NYSE American Company Guide. The Company’s continued li...
DSS, Inc. Announces Filing of Registration Statement on Form S-1 for I...
DSS, Inc. Announces Filing of Registration Statement on Form S-1 for Initial Public Offering of Impact Biomedical NEW YORK, Oct. 23, 2023 (GLOBE NEWSWIRE) -- DSS, Inc.(NYSE American: DSS) ("DSS") announced today that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission ("SEC") relating to the proposed initial public offering of the Company's wholly-owned subsidiary, Impact Biomedical (hyperlink: /). DSS, Inc. intends to list Impact Biomedical on the NYSE American exchange. The number of shares of Class A common stock to be offered and the pric...
DSS Inc. Issues Letter to Shareholders
DSS Inc. Issues Letter to Shareholders CEO Highlights Expected IPO of Impact Biomedical and Progress in Subsidiaries ROCHESTER, N.Y., Oct. 12, 2023 (GLOBE NEWSWIRE) -- DSS, Inc. (NYSE American: DSS), a multinational company operating nine (9) diversified business lines developed through strategic acquisitions to build shareholder value through periodic spinoffs to its shareholders, announced today that it has issued a Letter to Shareholders. Dear Valued Shareholders, On behalf of the management team at DSS, Inc., I am pleased to provide an update on our progress so far this year and o...
DSS Inc. Expands DSS Wealth Management, Inc.'s Management Team for Ram...
DSS Inc. Expands DSS Wealth Management, Inc.'s Management Team for Ramp Up of Asset Management Subsidiary Jim Monaghan Appointed Chief Operating Officer and Chief Compliance Officer; Michael Cheah Joins as Portfolio Manager and Head of Fixed Income ROCHESTER, N.Y., Sept. 06, 2023 (GLOBE NEWSWIRE) -- DSS Wealth Management, Inc., a wholly owned subsidiary of DSS, Inc. and advisor to DSS AmericaFirst Quantitative Funds, is pleased to announce that Jim Monaghan has joined as Chief Operating Officer and Chief Compliance Officer and Michael Cheah has joined DSS Wealth Management in the role o...
DSS Inc. Announces Distribution Date of August 8, 2023 for Spinoff of ...
DSS Inc. Announces Distribution Date of August 8, 2023 for Spinoff of Impact BioMedical Inc. DSS Shareholders of Record on July 10, 2023 to Receive Four Shares of Impact Biomedical Inc. for Every One Share of DSS, Inc. ROCHESTER, N.Y., July 31, 2023 (GLOBE NEWSWIRE) -- DSS, Inc. (“DSS” or the “Company”) (NYSE American: DSS), a multinational company operating nine business divisions through strategic acquisitions and development to build shareholder value through periodic spinoffs to shareholders, announced today the distribution date for the previously announced stock dividend of Impact...
DSS Inc. Appoints Daniel Lew as Chief Investment Officer and Portfolio...
DSS Inc. Appoints Daniel Lew as Chief Investment Officer and Portfolio Manager for DSS Wealth, Inc. ROCHESTER, N.Y., July 05, 2023 (GLOBE NEWSWIRE) -- DSS Wealth, Inc., a wholly owned subsidiary of DSS, Inc. and advisor to DSS AmericaFirst Quantitative Funds, is pleased to announce the appointment of Daniel Lew as Chief Investment Officer and Portfolio Manager. With over three decades of experience in investment management, security analysis, and institutional client advisory, Mr. Lew brings a wealth of knowledge and expertise to his new role. Mr. Lew's distinguished career spans various...
DSS Inc. Announces Updated Shareholder of Record Date for Spinoff of I...
DSS Inc. Announces Updated Shareholder of Record Date for Spinoff of Impact BioMedical Inc. Shareholders of Record on July 10, 2023 to Receive Four Shares of Impact Biomedical Inc. for Every One Share of DSS, Inc. on a Future Distribution Date ROCHESTER, N.Y., June 30, 2023 (GLOBE NEWSWIRE) -- DSS, Inc. (“DSS” or the “Company”) (NYSE American: DSS), a multinational company operating nine business divisions through strategic acquisitions and development to build shareholder value through periodic spinoffs, has filed for the distribution of a special stock dividend of Impact Biomedical In...
DSS, Inc. Announces Record and Distribution Date for Impact Biomedical...
DSS, Inc. Announces Record and Distribution Date for Impact Biomedical Spin-Off Special Dividend DSS Shareholders of Record on June 30 to Receive 4 Shares for Every 1 DSS Share ROCHESTER, N.Y., June 26, 2023 (GLOBE NEWSWIRE) -- DSS, Inc. (“DSS” or the “Company”) (NYSE American: DSS), a multinational company operating nine business divisions through strategic acquisitions and development to build shareholder value through periodic spinoffs, has filed for the distribution of a special stock dividend to DSS Inc. shareholders of record on June 30 for distribution on July 14, 2023. DSS shar...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.